Xenon Pharmaceuticals - XENE Stock Forecast, Price & News

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ:XENE opened at $38.18 on Wednesday. The company has a market cap of $2.38 billion, a price-to-earnings ratio of -20.86 and a beta of 1.53. The stock's 50-day moving average is $32.73 and its two-hundred day moving average is $31.16. Xenon Pharmaceuticals has a 1-year low of $14.65 and a 1-year high of $41.39.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Rating) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.06). Xenon Pharmaceuticals had a negative return on equity of 17.33% and a negative net margin of 432.24%. The firm had revenue of $0.54 million for the quarter, compared to analysts' expectations of $3.25 million. During the same quarter in the previous year, the company posted ($0.51) earnings per share. The firm's quarterly revenue was down 75.8% on a year-over-year basis. Equities research analysts anticipate that Xenon Pharmaceuticals will post -2.1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. JPMorgan Chase & Co. assumed coverage on Xenon Pharmaceuticals in a research note on Thursday, July 21st. They set an "overweight" rating and a $55.00 target price for the company. SVB Leerink raised their price target on Xenon Pharmaceuticals from $40.00 to $46.00 and gave the stock an "outperform" rating in a research report on Thursday, August 11th. StockNews.com upgraded Xenon Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Tuesday, August 9th. Finally, Wedbush raised their price target on Xenon Pharmaceuticals from $41.00 to $50.00 in a research report on Wednesday, August 10th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $47.83.

Insider Buying and Selling

In related news, Director Simon N. Pimstone sold 33,942 shares of the company's stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $37.76, for a total transaction of $1,281,649.92. Following the sale, the director now directly owns 58,058 shares in the company, valued at $2,192,270.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Xenon Pharmaceuticals news, Director Simon N. Pimstone sold 91,135 shares of the stock in a transaction that occurred on Friday, August 12th. The shares were sold at an average price of $38.28, for a total value of $3,488,647.80. Following the transaction, the director now directly owns 92,000 shares in the company, valued at $3,521,760. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Simon N. Pimstone sold 33,942 shares of the stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $37.76, for a total transaction of $1,281,649.92. Following the completion of the transaction, the director now owns 58,058 shares in the company, valued at $2,192,270.08. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 182,820 shares of company stock worth $6,982,432. Company insiders own 6.06% of the company's stock.